Характеристика и механизмы развития функциональных нарушений Т-лимфоцитов у больных лимфомами при проведении химиотерапии

Список литературы

1. Harris N.L., Jaffe E.S., Stein H. et al. A Revised European-American Classification of Lymphoid Neoplasms: A proposal from International Lymphoma study group. Blood, 1994, 84,1361−1392
2. Cheson B.D. ISH-ENA Combined Haematology Congress, Educational Program Book, 1998, pp 128−135
3. Shipp M.A., Harrington D.P., Andersen J. et al. International Non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-HodgkiiVs lymphoma. N. Engl. J. Med. 1993- 329: 987−94
4. Philip T, Gomez F, Guglielmi С et al. Bone marrow transplantation. 1998- 21 (Suppl.l): SI 79
5. Bartlett N., Rosenberg S., Hoppe R., at al. Brief chemotherapy Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease. A preliminary report. J Clin Oncol. 1995- Vol. 13- N 5: 1080−1088
6. Diehl V., Sieber M., Ruffer U. et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann of Oncol. 1997- 8: 143−148
7. Ferme C, et al. The MINE regimen or intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol 1995- 6:543
8. Lehrnbecher T, Foster C, Vazquez N et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 1997- 19: 399−417
9. Mackall Cr. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. The Oncologist 1999- 4: 370−378
10. Nagler A., Ackerstein A., Or R. et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997- 89: 3951−3959
11. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994- 78(4): 539−542
12. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993- 4: 41 47
13. Владимирская E, Масчан А, Румянцев А. Апоптоз и его роль в развитии опухолевого роста. Гематология и трансфузиология 1997- 42(5): 4−9
14. Погорелов В, Козинец Г. Морфология апоптоза при нормальном и патологическом гемопоэзе. Гематология и трансфузиология 1995- 40(5): 17−25
15. Heslop Н, Gottlieb D, Bianchi A et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood, Sep 1989- 74: 1374 1380
16. Banayai A., Paloczi K., Csipo I., e.a. Complement-mediated immune complex sulubilization and precipitation inhibition in sera of patients with non-Hodgkin's lymphoma. Haematologica. 1990, Vol.23, N2, p.87−96
17. Mehta В., Advani S., Nadkarni J. Non-Hodgkin's lymphoma: Natural cell-mediated cytotoxicity correlated with histological classification and prognosis. Oncology. 1989. Vol.46, N5, p.323−5
18. Fuks Z, Strober S, Bobrove AM et al. Long term effects of radiation on T and В lymphocytes in the peripheral blood of patients with Hodgkin’s disease. J Clin Invest 1986- 58: 803a-807a
19. Magrath IT, Simon RM. Immunosuppression in Burkitt’s lymphoma. Peripheral blood lymphocyte populations related to clinical status. Int J Cancer 1976- 18: 399−408
20. Krackhardt A., Harig S., Witzens M. et al. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002- 100: 167−173
21. Mackall C., Stein D., Fleisher T, et al. Prolonged CD4 depletion after sequential autologousperipheral blood progenitor cell infusion in children and young adults. Blood 2000- 96: 754−762
22. Bomberger C., Singh-Jairam M., Rodey G. et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998- 91: 2588−2600
23. Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993- 55: 1339−1346
24. Miller RA, Daley J, Ghalie R et al. Clonal analysis of T cell deficiencies in autotransplant recipients. Blood 1991- 77: 1845−1850
25. Mackall CM, Fleischer T, Brown M, Magrath I, Shad A, Horowitz M, Wexler L, Adde M, McClure L, Gress RE: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994- 84: 2221−28
26. Browne MJ, Hubbard SM, Longo DL et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 1986−104:338−344
27. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995- 13: 2431−2448
28. Shevach E. Certified professionals: CD4+CD25+ suppressor T cells. J. Exp. Med. 2001- 93: 41−45
29. Jonuleit H., Schmitt E., Stassen M. et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001- 193: 1285−1294
30. Levings M., Sangregorio R. and Roncarolo M-G. Human CD25+CD4+ T cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 2001- 193: 1295−1302
31. Thornton A. and Shevach E. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp.Med. 1998- 188: 287 296
32. Nakamura K., Kitani A. and Strober W. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor p. J. Exp. Med. 2001- 194: 629−644
33. Thornton A. and Shevach E. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000- 164: 183−190
34. Shimizu J., Yamazaki S., Takahashi T. et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002- 3(2): 135−142
35. McHugh R., Whitters M., Piccirillo C. et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002- 16(2): 311−323
36. Kanamaru F., Youngnak P, Hashiguchi M et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol 2004- 172:7306−7314
37. Ermann J and Fathman CG. Costimulatory signals controlling regulatory T cells. PNAS 2003- 100(26): 15 292−15 293
38. Tone M., Tone Y., Adams E. et al. From the cover: mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. PNAS 2003- 100: 15 059−15 064.
39. Dieckmann D., Bruett C., Ploettner H. et al. Human CD4+CD25+ regulatory, contact-dependent T ells induce interleukin 1-producing, contact-independent type 1 -like regulatory T cells. J. Exp. Med. 2002- 196(2): 247−253
40. Sarin A, Wu ML, Henkart P. Different interleukin-lp converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J Exp Med 1996- 184: 2445−2450
41. Badley D, Pilon A, Landay A, Lynch D. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000- 96(9): 2951−2964
42. Nagata, S., and P. Golstein. The Fas death factor. Science 1995- 267: 1449−1456
43. Miyawaki Т., Uehara Т., Nibu R. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 1992- 149: 3753−3758
44. Stahnke K., Fulda S., Freisen C., et al. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 2001- 98: 3066−3073
45. Hakim FT, Cepeda R, Kaimei S et al. Constraints on CD4 recovery post chemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997- 90: 3789−3798
46. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today 1997- 18: 245−251
47. Ageitos AG, Varney ML, Bierman PJ et al. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant 1999- 23: 63−69
48. Ageitos AG, Singh RK, Ino K, Ozerol I et al. IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: monocyte inhibition. J Immunother 1998- 21(6): 409−17
49. Ino K, Singh RK, Talmadge JE. Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol 1997- 61: 583−591
50. Ino Kazuhiko, Ageitos Ana G, Singh Rakesh K. Activation-induced T cell apoptosis by monocytes from stem cell products. International Immunopharmacology 2001- 1: 13 071 319
51. Gazitt Y. Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells 2000- 18: 390−398
52. Druilhe A., Cai Z., Haile S. et al. Fasmediated apoptosis in cultured human eosinophils. Blood 1996-. 87: 2822−2830
53. Iwai K., Miyawaki Т., Takizawa T. et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood 1994−84: 1201−1208
54. Liles W., Kiener P., Ledbetter J. et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 1996- 184: 429−440
55. Singh RK., Varney ML., Buyukberber S. et al. Fas-FasL-mediated CD4+ T-Cell Apoptosis following Stem Cell Transplantation. Cancer Research 1999- 59: 3107−3111
56. Badley AD., Dockrell D., Simpson M. et al. Macrophage-dependent apoptosis of CD4+T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997- 185: 55−64
57. Badley AD., McElhinny JA., Leibson PJ. et al. Up-regulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediated apoptosis of uninfected T lymphocytes. J. Virol. 1996- 70: 199−206
58. Kiener PA., Davis PM., Rankin BM. et al. Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation. J. Immunol. 1997, 159: 1594−1598
59. Kiener PA., Davis PM, Starling GC et al. Differential induction of apoptosis by Fas-FasL interaction in human monocytes and macrophages. J Exp Med 1997- 185: 1511
60. Schmidt M., Lugering N., Lugering A. Et al. Pole of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J. Immunol 2001- 166: 1344−1351
61. Oyaizu N, Adachi Y, Hashimoto F et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J. Immunol 1997- 158: 2456−2463
62. Brown S., Savill J. Phagocytosis triggers macrophage release of Fas ligand and induce apoptosis of bystander leukocytes. J. Immunol. 1999- 162: 480−485
63. Stravodimos K., Singhal P., Sharma S. et al. Escherichia coli promotes macrophage apoptosis. J. Endourol. 1999- 13: 273−277
64. Nwakoby I., Reddy K., Patel P. et al. Fas-Mediated Apoptosis of Neutrophils in Sera of Patients with Infection. Infection and Immunity 2001- 69: 3343−3349
65. Fadok V., Bratton D., Guthrie L. et al. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J. Immunol. 2001- 166: 6847−6854
66. Fadok V., Bratton D., Konowal A et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-b, PGE2, and PAF. J. Clin. Invest. 1998- 101: 890−898
67. Lucas M., Stuart L., Savill J and Lacy-Hulbert A. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J. Immunol. 2003- 171: 2610−2615
68. Cvetanovic M and Ucker D. Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. J. Immunol. 2004- 172: 880−889
69. Byrne A and Reen D. Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Immunol 2002- 168: 1968−1977
70. Voll R., Herrmann M., Roth E. et al. Immunosuppressive effects of apoptotic cells. Nature 1997−390:350−357
71. Zamboni D and Rabinovitch M. Phagocytosis of apoptotic cells increases the susceptibility of macrophages to infection with Coxiella burnetii phase II through down-modulation of nitric oxide production. Infection and Immunity 2004- 72: 2075−2080
72. Stuart L., Lucas M., Simpson C. et al. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 2002- 168: 1627−1635
73. Schultz J, Nadler L, Gribben J. B7-mediated costimulation and the immune response. Blood Rev. 1996- 10:111−127
74. Wells A., Walsh M., Bluestone J. et al. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 2001- 108: 895−904
75. Greenwald R., Boussiotis V., Lorsbach R. et al. CTLA-4 regulates induction of anergy in vivo. Immunity 2001- 14: 145−155
76. Hocevar B. and Howe P. Mechanisms of TGFb-induced cell cycle arrest. Miner. Electrolyte Metab. 1998- 24: 131−135
77. Miller C., Ragheb J. and Schwartz R. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med 1999- 190 (1): 53−64
78. Liang L and Sha W. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002- 14(3): 384−390
79. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003- 3(8): 609−620
80. Mielcarek M, Martin P and Torok-Storb B. Suppression of Alloantigen-Induced T-Cell Proliferation by CD 14+ Cells Derived From Granulocyte Colony-Stimulating Factor -Mobilized Peripheral Blood Mononuclear Cells. Blood 1997- 89:1629−1634
81. Groux H, Bigler M, de Vries JE et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996- 184: 19−27
82. Schwartz R. Models о f T Cell Anergy: is there a common molecular mechanism? J. Exp. Med. 1996- 184: 1−8
83. Becker J, Brabletz T, Kirchner T. Negative transcriptional regulation in anergic T cells. Proc. Natl. Acad. Sci. USA 1995- 92: 2375−2381
84. Powell J., Lerner C. and Schwartz R. Inhibition of cell cycle progression by rapamycin induce T cell clonal anergy even in the presence of costimulation. J. Immunol. 1999- 162: 2775−2784
85. Grundstrom S., Dohlsten M and Sundstedt A. IL-2 unresponsiveness in anergic CD41 T cells is due to defective signaling through the common g-chain of the IL-2 receptor. J. Immunol. 2000- 164: 1175−1180
86. Attinger A., Acha-Orbea H and MacDonald H. Cutting Edge: Cell autonomous rather than environmental factors control bacterial superantigen-induced T cell anergy in vivo. J. Immunol. 2000−165:1171−1174
87. Sundstedt A., Hoiden I., Rosendahl A. et al. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J. Immunol. 1997- 158: 180−186
88. Miller C., Ragheb J., and Schwartz R. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med. 1999- 190: 53−60
89. Schwartz RH. T cell anegry. Annu Rev Immunol. 2003- 21: 305−334
90. Chouaib S., Welte K., Mertelsmann R et al. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J. Immunol. 1985- 135: 1172−1179
91. Stephan R, Conrad P., Saizawa M et al. Prostaglandin E2 depresses antigen-presenting cell function of peritoneal macrophages. J. Surg. Res. 1988- 44: 733−739
92. Lingk D., Chan M. and Gelfand E. Increased cyclic adenosine monophosphate levels block progression but not initiation of human Tcell proliferation. J. Immunol. 1990- 145: 449−455
93. Choudhry M., Sarfraz Ahmad and Mohammed M Sayeed. Role of Ca2+ in prostaglandin E2-induced T-lymphocyte proliferative suppression in sepsis. Infection and Immunity 1995- 63 (8): 3101−3105
94. Paliogianni F., Kincaid R and Boumpas D. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathway. J. Exp. Med. 1993- 178: 1813−1817
95. Betz M. and Fox B. Prostaglandin E2 inhibits production of Thl lymphokines but not of Th2 lymphokines. J. Immunol. 1991- 146: 108−112
96. Gold K., Weyand С and Goronzy J. Modulation of helper T cell function by prostaglandins. Arthritis Rheum. 1994- 37: 925−929
97. De Vries J., de Waal Malefyt R., Yssel H et al. Do human TH1 and TH2 CD41 clones exist? Res. Immunol. 1991- 142: 59−64
98. Xiaowen He and John M. Stuart. Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. J. Immunol. 1999- 163: 6173−6179
99. Bras A., Rodriguez-Borlado L., Gonzalez-Garsia A. et al. Nitric Oxide regulates clonal expansion and activation-induced cell death triggered by staphylococcal enterotoxyn B. Infection and Immunity 1997- 65(10): 4030−4037
100. Bobe P., Benihoud K., Grandjon D. et al. Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood 1999- 94(3): 10 281 037
101. Bogdan C. The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med. 1998- 187(9): 1361−1365
102. Liew F.Y. Regulation of lymphocyte functions by nitric oxide. Curr. Opin. Immunol. 1995- 7: 396−399
103. Taylor-Robinson A., Liew F., Severn A. et al. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994- 24(4): 980−984
104. Strickland D., Kees U. and Holt P. Regulation of T-cell activation in the lung: alveolar acrophages induce reversible T-cell anergy in vitro associated with inhibition of interleukin-2 receptor signal transduction. Immunology 1996- 87- 250−258
105. Bingisser R., Tilbrook P., Holt P. and Kees U. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 1998- 160: 5729−5734
106. Niedbala W., Wei X., Campbell C. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor (32 expression via cGMP. PNAS 2002- 99: 16 186−16 191
107. Buttke T.M. and Sandstom P.A. Oxidative stress as a mediator of apoptosis. Immunol. Today 1994- 15: 7−10
108. Wesch D., Marx S., and Kabelitz D. Monocyte-dependent death of freshly isolated T-lymphocytes: induction by phorbolester and mitogens and differential effects of catalase. J. Immunol 1998- 161: 1248−1256
109. ITansson M., Asea A, Ersson U et al. Induction of apoptosis in NK cells by monocyte -derived reactive oxygen metabolites. J. Immunol. 1996- 156: 42−48
110. Mellqvist U., Hansson M., Brune M. et al. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000- 96: 1961−1968
111. Otsudji M., Kimura Y., Aoe T. et al. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 z chain of T-cell receptor complex and antigen-specific T-cell responses PNAS 1996- 93: 13 119−13 124
112. Sandstrom P., Mannie M. and Buttke T. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. J. Leukocyte Biol 1994- 55:221−227
113. Deas O., Dumont C., Mollereau B. Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. International Immunology 1997- 9(1): 117 125
114. Cemerski S., Cantagrel A., van Meerwijk J et al. Reactive oxygen species differentially affect T cell receptor-signalling pathways. J. Biol. Chemist. 2002- 227: 19 585−19 593
115. Allen R. and Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med. 2000- 28(3): 463−499
116. Malmberg K., Arulampalam V., Ichihara F. et al. Inhibition of activated/memory (CD45RO+) T cells by oxidative stress/ associated with block of NF-кВ activation. J. Immunol. 2001- 167: 2595−2601
117. Шевела Е.Я., Крючкова И. В., Норкин M.H. Роль моноцитов в развитии функциональных нарушений Т-клеток у больных лимфомами при проведении полихимиотерапии. Гематология и трансфузиология 2000- 45: 34−36
118. Крючкова И.В. Характеристика иммунных нарушений при развитии инфекционных осложнений у больных гемобластозами на программной полихимиотерапии. Дисс.канд. мед. наук. Новосибирск, 2000 г.
119. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998- 34(1): 39−43
120. Spielberger R., Stiff P., Bensinger W. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. N. Engl. J. Med. 2004- 351: 2590−2598
121. Miaskowski C. Biology of mucosal pain. J Nat Cancer Institute Monographs 2001- 29: 3740
122. Elting LS, Bodey GP, Keefe ВН. Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis 1992- 14: 12 011 207
123. Kostler W., Hejna M., Wenzel C. et al. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. С A Cancer J Clin 2001- 51: 290−315
124. Pico J., Avila-Garavito A., Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. The Oncologist 1998- 3: 446−451